Daniel Nevrivy
IP Attorney
Nevrivy Patent Law Group
Personal Profile
Daniel Nevrivy is an intellectual property attorney and he counsels clients on domestic and international IP procurement and enforcement. He has expertise in the life sciences and has successfully assisted clients for over 20 years in securing and protecting their intellectual property assets. He has drafted and prosecuted hundreds of domestic and international patent applications that span the entire breadth of technologies found in the life sciences, including therapeutic antibodies and biologics, genome editing, artificial intelligence-based prognosis and treatment, gene therapy, immunotherapies, vaccines, diagnostics, therapeutic methods, small molecules, drug formulation and delivery technologies, cell therapies, stem cells and regenerative medicine, and therapeutic devices. He has been involved in several IP due diligence audits on both the buy and sell sides of various transactions, including venture investment, licensing, and acquisition of intellectual property.
His practice further includes counseling pre-clinical and clinical stage life science corporations regarding intellectual property strategies and portfolio management. He has conducted numerous freedom-to-operate investigations; rendered numerous legal opinions regarding inventorship, patentability, non-infringement and invalidity of patents. In particular, he has significant experience helping companies navigate the complex intellectual property issues associated with the development and launch of proprietary products. He represented one of his pharmaceutical/medical device clients in U.S. District Court in a breach of contract, trademark infringement, unfair competition and defamation case, obtained enforcement of a preliminary injunction, and judgment including sanctions, compensatory, statutory and punitive damages of over $17M. See Aquavit Pharmacueticals, Inc. v. U-Bio Med, Inc., et al., Case No. 19-CV-3351 (VEC) (RWL) (SDNY).
He also maintains an active pro bono practice representing disabled U.S. veterans in their IP matters who are graduates of the Entrepreneurship Boot Camp (EBV) program run by Syracuse University.
During his doctoral studies he investigated transcriptional regulation mediated by steroid/thyroid hormone receptors, especially the retinoic acid receptor (RAR) and studied RAR-induced cell differentiation of pluripotent embryonal carcinoma (EC) cells. He identified and cloned a novel gene product (Grasp) regulated by RARs in EC cells and conducted experiments to elucidate the biological function of the gene product. He also assisted in the cloning and characterization of the novel transcription factor genes Bcl11a and Bcl11b, which are now highly studied and well characterized.
His practice further includes counseling pre-clinical and clinical stage life science corporations regarding intellectual property strategies and portfolio management. He has conducted numerous freedom-to-operate investigations; rendered numerous legal opinions regarding inventorship, patentability, non-infringement and invalidity of patents. In particular, he has significant experience helping companies navigate the complex intellectual property issues associated with the development and launch of proprietary products. He represented one of his pharmaceutical/medical device clients in U.S. District Court in a breach of contract, trademark infringement, unfair competition and defamation case, obtained enforcement of a preliminary injunction, and judgment including sanctions, compensatory, statutory and punitive damages of over $17M. See Aquavit Pharmacueticals, Inc. v. U-Bio Med, Inc., et al., Case No. 19-CV-3351 (VEC) (RWL) (SDNY).
He also maintains an active pro bono practice representing disabled U.S. veterans in their IP matters who are graduates of the Entrepreneurship Boot Camp (EBV) program run by Syracuse University.
During his doctoral studies he investigated transcriptional regulation mediated by steroid/thyroid hormone receptors, especially the retinoic acid receptor (RAR) and studied RAR-induced cell differentiation of pluripotent embryonal carcinoma (EC) cells. He identified and cloned a novel gene product (Grasp) regulated by RARs in EC cells and conducted experiments to elucidate the biological function of the gene product. He also assisted in the cloning and characterization of the novel transcription factor genes Bcl11a and Bcl11b, which are now highly studied and well characterized.
